Publications by authors named "Shannon Ferrante"

Claim this Profile
C
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors.
Philip J Mease, Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, Soumya D Chakravarty

Adv Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial and Ethnic Disparities in Treatment Initiation Among Patients with Newly Diagnosed Psoriatic Arthritis: A Retrospective Medicaid Claims Database Study.
Aarti A Patel, Shannon Allen Ferrante, Iris Lin, Alex Z Fu, Alicia K Campbell

Rheumatol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Antoine Bessou, Xavier Colin, Julie De Nascimento, Will Sopwith, Shannon Ferrante

Eur J Health Econ· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Peter Feng Wang, Christopher W Yee, Boris Gorsh, Miriam L Zichlin, Prani Paka, Shannon Ferrante

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals.
Chang Xu, Shannon A Ferrante, Timothy Fitzgerald, Christopher D Pericone, Bingcao Wu

J Manag Care Spec Pharm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
Feng Wang, Leah Sansbury, Shannon Ferrante, Eric M Maiese, Jenny Willson

J Med Econ· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Thibaud Prawitz, Rakesh Popat, Attaya Suvannasankha, Grammati Sarri, Rachel Hughes, Shannon Allen Ferrante

Adv Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of Severe Maternal Morbidity During Pregnancy in US Commercially Insured and Medicaid Populations: An Observational Study.
Kimberly K Vesco, Shannon Ferrante, Yong Chen, Thomas Rhodes, Christopher M Black

Matern Child Health J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Matthew Radford, Daniel C Parks, Shannon Ferrante, Yogesh Punekar

AIDS· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.
Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante

Expert Rev Hematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Yock Young Dan, Shannon A Ferrante, Elamin H Elbasha, Tun-Ying Hsu

Antivir Ther· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Kostas Athanasakis, Shannon Allen Ferrante, Ilias-Ioannis Kyriopoulos, Ioannis Petrakis, Mary Hill

Clin Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
Jagpreet Chhatwal, Shannon A Ferrante, Cliff Brass, Antoine C El Khoury, Margaret Burroughs

Value Health· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary.
Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

J Health Econ Outcomes Res· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.
Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass, Antoine C El Khoury, Fred Poordad

BMC Infect Dis· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
Elamin H Elbasha, Jagpreet Chhatwal, Shannon A Ferrante, Antoine C El Khoury, Pedro A Laires

Appl Health Econ Health Policy· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Karl J Krobot, Shannon Allen Ferrante, Michael J Davies, Thomas Seck, Gary E Meininger

Curr Med Res Opin· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study.
Timo Vesikari, Aino Karvonen, Shannon Allen Ferrante, Max Ciarlet

Eur J Pediatr· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine.
Timo Vesikari, Aino Karvonen, Shannon Allen Ferrante, Barbara J Kuter, Max Ciarlet

Pediatr Infect Dis J· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis